Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.34 USD | +7.00% | -1.21% | +96.26% |
Mar. 21 | Fate Therapeutics, Inc. announced that it has received $19.996366 million in funding from Redmile Group, LLC | CI |
Mar. 19 | Fate Therapeutics Prices $100 Million Offering, Private Placement | MT |
Financials (USD)
Sales 2024 * | 4.73M | Sales 2025 * | 4.85M | Capitalization | 835M |
---|---|---|---|---|---|
Net income 2024 * | -195M | Net income 2025 * | -211M | EV / Sales 2024 * | 134 x |
Net cash position 2024 * | 202M | Net cash position 2025 * | 124M | EV / Sales 2025 * | 147 x |
P/E ratio 2024 * |
-4.15
x | P/E ratio 2025 * |
-4.45
x | Employees | 181 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.53% |
Latest transcript on Fate Therapeutics, Inc.
1 day | +7.00% | ||
1 week | -1.21% | ||
Current month | +3.53% | ||
1 month | -1.61% | ||
3 months | +100.55% | ||
6 months | +249.52% | ||
Current year | +96.26% |
Managers | Title | Age | Since |
---|---|---|---|
J. Wolchko
FOU | Founder | 53 | 07-04-26 |
Edward Dulac
DFI | Director of Finance/CFO | 49 | 20-08-16 |
Chairman | 75 | 11-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Epstein
BRD | Director/Board Member | 69 | 14-03-16 |
Robert Hershberg
BRD | Director/Board Member | 61 | 20-04-30 |
Tim Coughlin
BRD | Director/Board Member | 57 | 13-07-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.95% | 0 M€ | 0.00% | - | |
2.10% | 1 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 7.34 | +7.00% | 2,110,595 |
24-03-26 | 6.86 | -0.15% | 2,942,788 |
24-03-25 | 6.87 | +3.93% | 1,986,574 |
24-03-22 | 6.61 | -11.04% | 1,997,087 |
24-03-21 | 7.43 | 0.00% | 1,991,588 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+96.26% | 835M | |
+2.56% | 108B | |
+10.02% | 104B | |
+7.45% | 23.66B | |
-11.91% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-14.02% | 16.19B | |
+4.61% | 13.72B | |
+35.05% | 12.22B |